Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) of Lung or Gastroenteropancreatic (GEP) Origin. A Phase II Multicohort Trial (DUNE Trial / GETNE 1601)

被引：0
|
作者：
Hernando-Cubero, J. [1 ]
Manzano, J. L. [2 ]
Benavent, M. [3 ]
Lopez, C. [4 ]
Teule, R. [5 ]
Garcia-Carbonero, R. [6 ]
Carmona-Bayonas, A. [7 ]
Crespo, G. [8 ]
Cubillo, A. [9 ]
Jimenez-Fonseca, P. [10 ]
LaCasta, A. [11 ]
Capdevila, J. [1 ]
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Inst Catala Oncol Badalona, Barcelona, Spain
[3] Hosp Virgen del Rocio, Seville, Spain
[4] Hosp Univ Marques de Valdecilla, Santander, Spain
[5] Inst Catala Oncol Hosp, Barcelona, Spain
[6] Hosp Univ 12 Octubre, Madrid, Spain
[7] HJM Morales Meseguer, Murcia, Spain
[8] Hosp Univ Burgos, Burgos, Spain
[9] Hosp Univ Madrid Sanchinarro, Madrid, Spain
[10] Hosp Univ Cent Asturias, Oviedo, Spain
[11] Hosp Univ Donostia, San Sebastian, Spain
来源：
NEUROENDOCRINOLOGY | 2018年 / 106卷
关键词：
durvalumab; tremelimumab; neuroendocrine; immunotherapy;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
J10
引用
收藏
页码：228 / 228
页数：1
相关论文
共 50 条
  • [1] A multicohort phase II study of durvalumab plus tremelimumab for the treatment of patients (PTS) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or lung origin (the DUNE trial-GETNE1601-).
    Garcia, Ignacio Matos
    Grande, Enrique
    Garcia-Carbonero, Rocio
    Lopez, Carlos
    Teule, Alexandre
    Capdevila, Jaume
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)
    Capdevila, J.
    Teule, A.
    Lopez, C.
    Garcia-Carbonero, R.
    Benavent, M.
    Custodio, A.
    Cubillo, A.
    Alonso, V.
    Alonso Gordoa, T.
    Carmona-Bayonas, A.
    Crespo, G.
    Blanco-Codesido, M.
    Jimenez-Fonseca, P.
    Viudez, A.
    La Casta Munoa, A.
    Sevilla, I.
    Llanos, M.
    Segura, A.
    Hernando-Cubero, J.
    Manzano, J. L.
    ANNALS OF ONCOLOGY, 2020, 31 : S770 - S771
  • [3] Final results from the DUNE trial (GETNE 1601): Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins
    Capdevila, J.
    Teule, A.
    Hernando, J.
    Lopez, C.
    Garcia-Carbonero, R.
    Vinuales, Benavent
    Custodio, A.
    Cubillo, A.
    Alonso, V
    Landolfi, S.
    Alvarez A, Garcia
    Manzano, J. L.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 170 - 170
  • [4] Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)
    Hernando, J.
    Manzano, J. L.
    Teule, A.
    Lopez, C.
    Garcia-Carbonero, R.
    Benavent Vinuales, M.
    Custodio, A.
    Cubillo, A.
    Alonso, V.
    Alonso-Gordoa, T.
    Carmona-Bayonas, A.
    Crespo, G.
    Blanco, M.
    Jimenez-Fonseca, P.
    Viudez, A.
    La Casta, A.
    Sevilla, I.
    Llanos, M.
    Segura, A.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S909 - S910
  • [5] Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601)
    Capdevila, J.
    Landolfi, S.
    Hernando, J.
    Teule, A.
    Garcia-Carbonero, R.
    Custodio, A.
    Cubillo, A.
    Alonso-Gordoa, T.
    Carmona-Bayonas, A.
    Crespo, G.
    Blanco, M.
    Viudez, A.
    La Casta, A.
    Sevilla, I.
    Segura, A.
    Lopez, C.
    Benavent Vinuales, M.
    Nuciforo, P.
    Manzano, J. L.
    ANNALS OF ONCOLOGY, 2021, 32 : S914 - S915
  • [6] Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
    J. Capdevila
    J. Hernando
    A. Teule
    C. Lopez
    R. Garcia-Carbonero
    M. Benavent
    A. Custodio
    A. Garcia-Alvarez
    A. Cubillo
    V. Alonso
    A. Carmona-Bayonas
    T. Alonso-Gordoa
    G. Crespo
    P. Jimenez-Fonseca
    M. Blanco
    A. Viudez
    A. La Casta
    I. Sevilla
    A. Segura
    M. Llanos
    S. Landolfi
    P. Nuciforo
    J. L. Manzano
    Nature Communications, 14
  • [7] Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
    Capdevila, J.
    Hernando, J.
    Teule, A.
    Lopez, C.
    Garcia-Carbonero, R.
    Benavent, M.
    Custodio, A.
    Garcia-Alvarez, A.
    Cubillo, A.
    Alonso, V.
    Carmona-Bayonas, A.
    Alonso-Gordoa, T.
    Crespo, G.
    Jimenez-Fonseca, P.
    Blanco, M.
    Viudez, A.
    La Casta, A.
    Sevilla, I.
    Segura, A.
    Llanos, M.
    Landolfi, S.
    Nuciforo, P.
    Manzano, J. L.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [8] Durvalumab plus tremelimumab for the treatment of patients (pts) with refractory and progressive advanced thyroid carcinoma: A phase II multicohort trial (DUTHY / GETNE T1812)
    Hernando Cubero, J.
    Taberna Sanz, M.
    Carmona Bayonas, A.
    Iglesias, L.
    Grande, E.
    Trigo Perez, J. M.
    Grau, J. J.
    Lopez-Picazo, J. M.
    Castelo, B.
    Alonso Gordoa, T.
    Lorenzo, I.
    Casado Herraez, A.
    Ugidos, L.
    Munarriz, J.
    Lavernia, J.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 759 - 759
  • [9] Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914)
    Grande, E.
    Garcia-Carbonero, R.
    Teule, A.
    Benavent Vinuales, M.
    Jimenez-Fonseca, P.
    Molina-Cerrillo, J.
    Lopez, C.
    Custodio, A.
    Hierro, C.
    Gallego, J.
    Alonso, V.
    Carmona-Bayonas, A.
    Llanos, M.
    Sevilla, I.
    Hernando, J.
    Lista, F.
    Anton Pascual, B.
    Ruffinelli, J. C.
    Gallego Jimenez, I.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S624 - S625
  • [10] Cabozantinib plus atezolizumab in patients with advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II trial (CABATEN / GETNE-T1914).
    Hernando, Jorge
    Molina-Cerrillo, Javier
    Grande, Enrique
    Benavent Vinuales, Marta
    Garcia-Carbonero, Rocio
    Teule, Alex
    Custodio, Ana
    Jimenez-Fonseca, Paula
    Hierro, Cinta
    Lopez Lopez, Carlos
    Sevilla, Isabel
    Llanos, Marta
    Carmona-Bayonas, Alberto
    Alonso, Vicente
    Gallego, Javier
    Gallego Jimenez, Inmaculada
    Orta, Alberto
    Franco, Fernando
    Garcia-Alvarez, Alejandro
    Capdevila, Jaume
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345